After the DMP Stock touched and rebounced from it's 52-Week support at 36,00€, it is now creating a broadening rising wedge formation. As from market perspective, this formation can be attributed to high uncertainty as well as worsening growth perspective for the Euro-Zone.
Mid-term perspective for the stock is bearish. Rising broadening wedge will most probably break downwards and reach statgnation at support (36,00€).
Nevertheless, this formation can be exploited to do swing-traiding.
Keep in mind, that a negative forecast on the quarterly earnings report would most probably send the stock on a downwards tumble.
The acquisition of the french company Arkopharma in early August shows the general spirit of diversification from the predominantly COVID19-vaccine based earnings in 2021 towards it's historical core business (patent-free drugs).
This earnings report could very well give the longterm oriented investors an insight in the challenges or succeses that Dermapharm is facing at integrating the freshly acquired Arkopharma and thus give clarity (which would most likely lead to lower volatility figures).
Generally speaking, at a P/E ratio of under 12 and a current dividend yield of over 5%, all 5 analysts agree on a "BUY" recomendation.
Mid-term perspective for the stock is bearish. Rising broadening wedge will most probably break downwards and reach statgnation at support (36,00€).
Nevertheless, this formation can be exploited to do swing-traiding.
Keep in mind, that a negative forecast on the quarterly earnings report would most probably send the stock on a downwards tumble.
The acquisition of the french company Arkopharma in early August shows the general spirit of diversification from the predominantly COVID19-vaccine based earnings in 2021 towards it's historical core business (patent-free drugs).
This earnings report could very well give the longterm oriented investors an insight in the challenges or succeses that Dermapharm is facing at integrating the freshly acquired Arkopharma and thus give clarity (which would most likely lead to lower volatility figures).
Generally speaking, at a P/E ratio of under 12 and a current dividend yield of over 5%, all 5 analysts agree on a "BUY" recomendation.